Dilgard6.25 mg

Dilgard is indicated for the following conditions, with evidence strength noted for each:

• Chronic heart failure (mild to severe), established/FDA-approved: Dilgard is used, in addition to standard therapy (diuretics, ACE inhibitors/ARBs, and digoxin where appropriate), to reduce the risk of death and hospitalization in patients with heart failure of ischemic or cardiomyopathic origin.
• Left ventricular (LV) dysfunction after myocardial infarction, established/FDA-approved: Dilgard is used in clinically stable patients who have survived the acute phase of a heart attack and have a left ventricular ejection fraction of 40% or less, with or without symptomatic heart failure, to reduce cardiovascular mortality.
• Essential hypertension, established/FDA-approved: Dilgard is used alone or in combination with other antihypertensive agents, particularly thiazide diuretics, to lower blood pressure.
• Angina pectoris, guideline-supported/regionally approved use: Dilgard is used in some markets for chronic stable angina, based on its beta-blocking action.

Dilgard should always be used exactly as prescribed by a physician, and any change in dose or indication should be made only under medical supervision.

Each tablet of Carvedilol contains Carvedilol as the active ingredient, commonly available in strengths of 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg. Tablets also contain standard pharmaceutical excipients such as fillers, binders, and coating agents that do not have independent pharmacological activity. Patients should check the product label or ask their pharmacist for the exact strength and inactive ingredients of the specific brand dispensed.

Dilgard is a non-selective beta-adrenergic blocking agent that also possesses alpha-1 adrenergic blocking activity, making it a combined alpha/beta-blocker. It is used primarily in the long-term management of chronic heart failure, hypertension, and left ventricular dysfunction following a heart attack. By blocking beta-1 and beta-2 receptors, Dilgard reduces heart rate and cardiac workload, while its alpha-1 blocking action produces peripheral vasodilation, helping to lower blood pressure and reduce the strain on a weakened heart. Dilgard has been used in clinical practice since the 1990s and remains a well-established therapy in cardiovascular medicine.

Dilgard belongs to the therapeutic class of non-selective beta-blockers with alpha-1 blocking activity (combined alpha/beta-adrenergic antagonists). It is used in the broader categories of antihypertensive agents and heart failure therapy.

Carvedilol is a non-selective competitive antagonist at beta-1 and beta-2 adrenergic receptors, and a selective antagonist at alpha-1 adrenergic receptors. This dual mechanism distinguishes Carvedilol from purely beta-selective agents.

• Beta-blockade: Reduces heart rate, myocardial contractility, and cardiac output, decreasing myocardial oxygen demand and helping to control blood pressure and arrhythmic risk.
• Alpha-1 blockade: Produces peripheral vasodilation, which lowers systemic vascular resistance and blood pressure, and reduces the afterload on the heart.
• Additional properties: Carvedilol has demonstrated antioxidant (free-radical scavenging) and antiproliferative effects in laboratory studies, which may contribute to its cardioprotective benefits, though the precise clinical relevance of these ancillary properties is not fully established.

Carvedilol has no intrinsic sympathomimetic activity. It is well absorbed orally, undergoes significant first-pass hepatic metabolism (largely via CYP2D6 and CYP2C9), and is highly protein bound. Its elimination half-life is approximately 7-10 hours, generally supporting twice-daily dosing.

Dilgard should be taken by mouth, consistently with food, to minimize the risk of dizziness and low blood pressure on standing. It is usually given twice daily, at approximately the same times each day. Tablets should be swallowed whole with a glass of water. Patients should rise slowly from sitting or lying positions, especially when starting therapy or after a dose increase, to reduce the risk of falls from orthostatic hypotension.

Dilgard has several clinically significant drug interactions:

• Digoxin: Dilgard can increase digoxin blood levels; digoxin levels and heart rate should be monitored closely when Dilgard is started, adjusted, or stopped.
• Rifampin: Reduces Dilgard blood concentrations substantially, which may reduce its effectiveness.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine): May increase Dilgard blood levels, increasing the risk of side effects.
• Calcium channel blockers (verapamil, diltiazem): Combined use with Dilgard increases the risk of serious heart rhythm and conduction disturbances, severe bradycardia, and hypotension.
• Clonidine and other antihypertensive/centrally acting agents: Increased risk of profound hypotension and bradycardia; special care is needed if clonidine is being discontinued in a patient also taking Dilgard.
• Insulin and oral antidiabetic medicines: Dilgard may enhance the blood-sugar-lowering effect and can mask warning signs of hypoglycemia such as a fast heartbeat; blood glucose should be monitored closely.
• Amiodarone: May increase Dilgard levels and the risk of bradycardia and conduction abnormalities.
• Anesthetic agents and other cardiac depressant drugs: May potentiate the blood-pressure-lowering and cardiac-depressant effects of Dilgard.

Patients should inform their physician or pharmacist about all prescription medicines, over-the-counter drugs, and herbal supplements they are taking before starting Dilgard.

Side effects of Dilgard vary somewhat by indication but commonly include:

• Very common/common: Dizziness, fatigue, weakness, headache, low blood pressure (including orthostatic hypotension on standing), slow heart rate (bradycardia), diarrhea or other gastrointestinal upset, and elevated blood sugar (hyperglycemia).
• Less common: Fluid retention/swelling of the legs or ankles, weight gain, shortness of breath, dry mouth or eyes, blurred vision, cold hands and feet, and reduced libido or erectile difficulty.
• Rare but serious: Worsening of heart failure symptoms, severe allergic reactions (including Stevens-Johnson syndrome and anaphylaxis), significant liver function abnormalities, blood cell count abnormalities (such as aplastic anemia or low platelets), and inflammation of the lungs (interstitial pneumonitis).

Patients should seek prompt medical attention for fainting, very slow heart rate, severe dizziness, difficulty breathing, chest pain, signs of liver problems (yellowing of the skin/eyes, dark urine), or any signs of a severe allergic or skin reaction while taking Dilgard.

Pregnancy: Data on the use of Dilgard in pregnant women are limited. Beta-blockers as a class have been associated with fetal growth restriction, bradycardia, and hypoglycemia in the newborn when used in pregnancy, particularly in the third trimester. Dilgard should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close specialist supervision.

Lactation: It is not known whether Dilgard passes into human breast milk in clinically significant amounts. Because of the potential for serious adverse effects in a nursing infant (such as low heart rate or low blood sugar), a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Dilgard, taking into account the importance of the medicine to the mother.

Any use of Dilgard during pregnancy or while breastfeeding must be discussed with and supervised by a qualified physician.

Do not stop Dilgard abruptly. Sudden discontinuation of Dilgard, particularly in patients with underlying coronary artery disease, can precipitate rebound angina, worsening heart rhythm problems (arrhythmia), or even a heart attack (myocardial infarction). If discontinuation is necessary, the dose must be gradually reduced (tapered) over one to two weeks under close medical supervision, and the patient should be advised to limit physical activity during this period.

Bronchospastic disease: Even though Dilgard is contraindicated in bronchial asthma, patients with other bronchospastic conditions such as chronic bronchitis or emphysema who do not respond to or cannot tolerate other treatment may use Dilgard only under specialist supervision, generally at the lowest effective dose, because beta-blockade can worsen airway constriction.

Diabetes mellitus: Dilgard can mask important warning signs of low blood sugar (hypoglycemia), such as a fast heart rate, and may affect blood glucose control. Diabetic patients should monitor their blood sugar closely, especially when starting or adjusting Dilgard.

Peripheral vascular disease and Prinzmetal's (variant) angina: Dilgard should be used with caution, as beta-blockade may worsen symptoms of peripheral arterial insufficiency, and unopposed alpha-adrenergic activity from beta-blockade could theoretically worsen coronary artery spasm.

Heart block and bradycardia: Dilgard should be used cautiously in patients with first-degree AV block or a tendency toward slow heart rates; the dose should be reduced or the medicine stopped if the heart rate falls too low.

Hepatic impairment: Dilgard should be avoided in patients with severe liver disease and used cautiously, with monitoring, in those with mild to moderate hepatic impairment.

Surgery/anesthesia: Patients undergoing major surgery should inform their anesthetist that they are taking Dilgard, as it may enhance the effects of certain anesthetic agents on blood pressure and heart rate.

Take with food to reduce the risk of dizziness or fainting from a sudden drop in blood pressure upon standing.

Overdose of Dilgard is a medical emergency. Symptoms can include severe low blood pressure, very slow heart rate (bradycardia), heart failure, cardiogenic shock, difficulty breathing or bronchospasm, loss of consciousness, and generalized seizures. In case of a suspected overdose of Dilgard, seek immediate medical attention or contact emergency services/poison control right away. Do not wait for symptoms to appear. Treatment is generally supportive and may include close monitoring of heart rhythm and blood pressure in a hospital setting; general measures should be initiated by trained medical personnel and may include agents to raise heart rate and blood pressure, given the prolonged effects of Dilgard after overdose. Do not attempt to manage a Dilgard overdose at home.

Store Dilgard at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Older adults may be more sensitive to the blood-pressure-lowering effects of Dilgard; a lower starting dose and slower titration may be appropriate, with close monitoring for dizziness and falls.

Renal impairment: No specific dose adjustment of Dilgard is generally required for patients with kidney impairment, but such patients should be monitored, particularly at initiation of therapy.

Hepatic impairment: Dilgard is largely metabolized by the liver; it is contraindicated in severe hepatic impairment and should be used with caution and close monitoring in mild to moderate hepatic impairment.

Diabetic patients: Dilgard may mask symptoms of hypoglycemia and can affect blood glucose control; closer monitoring of blood sugar is recommended.

Patients with peripheral vascular disease: Dilgard should be used cautiously, as beta-blockade may aggravate symptoms of arterial insufficiency in the limbs.

Pediatric patients: Safety and effectiveness of Dilgard have not been well established in children; use in this population is generally not recommended outside of specialist pediatric cardiology supervision (see Pediatric Uses).

Dilgard is typically used as a long-term, often lifelong, maintenance therapy for chronic heart failure, hypertension, and left ventricular dysfunction after a heart attack, since these are chronic conditions requiring ongoing treatment. The duration of treatment should be determined by the prescribing physician based on the individual's condition and response to therapy. Dilgard should be continued as prescribed even if the patient feels well, and should never be stopped or the dose changed without first consulting the physician, given the risk of rebound cardiac events with abrupt discontinuation.

Carvedilol is classified as a non-selective beta-adrenergic receptor blocker with additional alpha-1 adrenergic receptor blocking activity. It belongs to the broader pharmacological group of antihypertensive and anti-heart-failure agents known as combined alpha/beta-blockers.

Carvedilol works by blocking beta-1 and beta-2 adrenergic receptors, which reduces heart rate, cardiac contractility, and renin release, thereby lowering the workload on the heart and helping to control blood pressure. At the same time, Carvedilol blocks alpha-1 adrenergic receptors located in blood vessel walls, causing the blood vessels to relax (vasodilation) and further reducing blood pressure and the resistance the heart must pump against. This combined alpha/beta-blocking action, along with possible antioxidant effects, contributes to the cardioprotective benefits of Carvedilol in heart failure and after a heart attack.

The safety and effectiveness of Dilgard in pediatric patients have not been well established by robust controlled trials, and Dilgard is generally not approved for routine use in children. Some specialist pediatric cardiology centers have used Dilgard off-label in children with heart failure due to congenital or acquired heart disease, under close specialist supervision, but this is not a standard or FDA-approved indication. Dilgard should be given to a child only if a pediatric specialist has specifically prescribed it, with careful weight-based dosing and close monitoring for low blood pressure, slow heart rate, and low blood sugar. Parents/caregivers should never give Dilgard to a child without explicit medical direction.